1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. France >
  5. Novartis Acquires Advanced Accelerator Applications S.A.

M&A Deal Summary

Novartis Acquires Advanced Accelerator Applications S.A.

On October 30, 2017, Novartis acquired life science company Advanced Accelerator Applications S.A.

Acquisition Highlights
  • This is Novartis’ 13th transaction in the Life Science sector.
  • This is Novartis’ 1st transaction in France.

M&A Deal Summary
Date 2017-10-30
Target Advanced Accelerator Applications S.A.
Sector Life Science
Buyer(s) Novartis
Deal Type Add-on Acquisition

Target

Advanced Accelerator Applications S.A.

Saint-Genis-Pouilly, France
Advanced Accelerator Applications S.A. is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera® (177Lu-DOTATATE), a first-in-class RLT product for neuroendocrine tumors (NETs). Radiopharmaceuticals, such as Lutathera, are unique medicinal formulations containing radioisotopes that are used clinically for both diagnosis and therapy. AAA was formed in 2002 and is based in Saint-Genis-Pouilly, France.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Novartis

Basel, Switzerland
Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 51.8B USD (2024)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.

DEAL STATS #
Overall 16 of 36
Sector: Life Science M&A 13 of 30
Type: Add-on Acquisition M&A Deals 14 of 30
Country: France M&A 1 of 1
Year: 2017 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-03-07 Genoptix

Carlsbad, California, United States

Genoptix, Inc. is one of the largest hematopathology testing laboratories in the U.S., providing thousands of oncologists and pathologists across the United States with comprehensive testing solutions in hematology and solid tumor molecular profiling. Genoptix, Inc. was founded in 1999 and is based in Carlsbad, California.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-04-09 AveXis

Dallas, Texas, United States

AveXis is a clinic-ready, synthetic biology platform company. AveXis has several ongoing clinical studies for the treatment of SMA, an inherited neurodegenerative disease caused by a defect in a single gene, the survival motor neuron (SMN1). The lead AveXis gene therapy candidate, AVXS-101, has highly compelling clinical data in treating SMA Type 1, which is the number one genetic cause of death in infants, where 9 out of 10 infants do not live to their second birthday or are permanently ventilator dependent. It is estimated that one out of every 6,000-10,000 children born is affected by some form of SMA.

Buy $8.7B
Mergr

Solution for

Product

Company

Legal